We used this model here to evaluate a combination study of an antibody targeting pGlu3-Aβ, m6 (murine PBD-C06), and Varoglutamstat (PQ912), the first in class glutaminyl cyclase inhibitor in clinical development for treatment of AD [32]. This evidence concerns the gene QPCT and Alzheimer disease.